DK2585064T3 - C5aR antagonists - Google Patents
C5aR antagonists Download PDFInfo
- Publication number
- DK2585064T3 DK2585064T3 DK11799027.5T DK11799027T DK2585064T3 DK 2585064 T3 DK2585064 T3 DK 2585064T3 DK 11799027 T DK11799027 T DK 11799027T DK 2585064 T3 DK2585064 T3 DK 2585064T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- compound
- compounds
- group
- vol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/823,039 US20100311753A1 (en) | 2008-12-22 | 2010-06-24 | C5aR ANTAGONISTS |
US13/072,616 US20110275639A1 (en) | 2008-12-22 | 2011-03-25 | C5aR ANTAGONISTS |
PCT/US2011/041910 WO2011163640A1 (en) | 2010-06-24 | 2011-06-24 | C5ar antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2585064T3 true DK2585064T3 (en) | 2017-07-24 |
Family
ID=47996916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11799027.5T DK2585064T3 (en) | 2010-06-24 | 2011-06-24 | C5aR antagonists |
Country Status (14)
Country | Link |
---|---|
US (7) | US9126939B2 (sr) |
EP (1) | EP2585064B1 (sr) |
JP (3) | JP2013529647A (sr) |
CN (1) | CN103068385B (sr) |
BR (1) | BR112012033075B1 (sr) |
DK (1) | DK2585064T3 (sr) |
ES (1) | ES2632975T3 (sr) |
HR (1) | HRP20171176T1 (sr) |
HU (1) | HUE033644T2 (sr) |
PL (1) | PL2585064T3 (sr) |
PT (1) | PT2585064T (sr) |
RS (1) | RS56332B1 (sr) |
SI (1) | SI2585064T1 (sr) |
WO (1) | WO2011163640A1 (sr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2734746T3 (es) | 2008-12-22 | 2019-12-11 | Chemocentryx Inc | Antagonistas de C5aR |
US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
HUE052252T2 (hu) | 2014-01-13 | 2021-04-28 | Aurigene Discovery Tech Ltd | Eljárás IRAK4 inhibitorként rák kezelésére alkalmas oxazolo[4,5-b]piridin és tiazolo[4,5-b]piridin származékok elõállítására |
CA2952188A1 (en) * | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
PT3200791T (pt) * | 2014-09-29 | 2020-05-06 | Chemocentryx Inc | Processos e intermediários na preparação de antagonistas c5ar |
CA3010735C (en) * | 2016-01-14 | 2023-06-13 | Chemocentryx, Inc. | Use of n-benzoyl-2-phenyl-3-phenylcarbamoyl-piperidin derivative for treating complement 3 glomerulopathy |
SG11201808625QA (en) * | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
RS64411B1 (sr) | 2017-03-31 | 2023-09-29 | Aurigene Oncology Ltd | Jedinjenja i kompozicije za lečenje hematoloških poremećaja |
CA3058023A1 (en) | 2017-04-03 | 2018-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
EP3630774B1 (en) | 2017-05-31 | 2022-11-23 | ChemoCentryx, Inc. | 5-5 fused rings as c5a inhibitors |
KR102638253B1 (ko) | 2017-05-31 | 2024-02-16 | 케모센트릭스, 인크. | C5a 억제제로서의 6-5 융합 고리 |
SG11201912882QA (en) | 2017-06-23 | 2020-01-30 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
FI3704108T3 (fi) | 2017-10-31 | 2024-05-23 | Curis Inc | Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon |
US20190134020A1 (en) * | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
KR20200109316A (ko) | 2017-12-22 | 2020-09-22 | 케모센트릭스, 인크. | C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물 |
EP3728202A4 (en) | 2017-12-22 | 2021-05-26 | ChemoCentryx, Inc. | DIARYL-SUBSTITUTED 5,5-CONDENSED RING COMPOUNDS AS C5AR INHIBITORS |
SI3737684T1 (sl) * | 2018-01-10 | 2023-01-31 | Idorsia Pharmaceuticals Ltd | Derivati 2,4,6,7-tetrahidro-pirazolo(4,3-D)pirimidin-5-ona in sorodne spojine kot modulatorji receptorja C5A za zdravljenje vaskulitisa in vnetnih bolezni |
WO2019141808A1 (en) * | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
JP7337833B2 (ja) * | 2018-04-02 | 2023-09-04 | ケモセントリックス,インコーポレイティド | 縮合二環式C5aRアンタゴニストのプロドラッグ |
CN108558844A (zh) * | 2018-05-16 | 2018-09-21 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
CN108727355A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
CN108727354A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
CN108440513A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
CN108440514A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
CN112423752A (zh) | 2018-06-07 | 2021-02-26 | 凯莫森特里克斯股份有限公司 | C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 |
FI3886820T3 (fi) | 2018-11-30 | 2023-05-25 | Chemocentryx Inc | Kapseliformulaatioita |
WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
US11026935B2 (en) | 2019-11-08 | 2021-06-08 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
AU2020380367A1 (en) | 2019-11-08 | 2022-05-12 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
US11603356B2 (en) * | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
CA3172421A1 (en) | 2020-03-27 | 2021-09-30 | Niels C. Riedemann | Inhibitors of c5a for the treatment of corona virus infection |
WO2022028586A1 (en) * | 2020-08-07 | 2022-02-10 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as c5ar inhibitors |
WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
US11844790B2 (en) | 2020-10-28 | 2023-12-19 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
CN117402104A (zh) * | 2021-12-06 | 2024-01-16 | 重庆医科大学 | 阿伐可泮手性中间体的制备方法 |
WO2023158722A2 (en) * | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
EP1087937A1 (en) * | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
IL141724A0 (en) | 1998-08-28 | 2002-03-10 | Scios Inc | INHIBITORS OF P38-α KINASE |
WO2001085720A1 (en) | 2000-05-05 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
KR100802332B1 (ko) | 2000-08-10 | 2008-02-13 | 미쯔비시 웰 파마 가부시키가이샤 | 신규한 3-치환된 요소 유도체 및 그의 의학적 용도 |
AU2001290873B2 (en) * | 2000-09-11 | 2006-07-27 | Sepracor Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
KR100884709B1 (ko) | 2000-09-14 | 2009-02-19 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 아미드 유도체의 광학 활성체 및 그의 의약적 용도 |
AU7622500A (en) | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
DE10231789A1 (de) | 2001-07-19 | 2003-02-06 | Luk Lamellen & Kupplungsbau | Verfahren, Vorrichtung und deren Verwendung zum Betrieb eines Kraftfahrzeuges |
JP4958387B2 (ja) | 2001-08-17 | 2012-06-20 | ジェネンテック, インコーポレイテッド | C5bの形成を妨害することなくc5及びc5aに結合する補体経路阻害剤 |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
WO2003082826A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
EP1490044A4 (en) | 2002-03-29 | 2008-04-16 | Neurogen Corp | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
AU2003265625A1 (en) | 2002-08-21 | 2004-03-11 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
AU2003290605A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US8071624B2 (en) | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
JP4058106B2 (ja) | 2005-02-18 | 2008-03-05 | アストラゼネカ アクチボラグ | 抗菌性のピペリジン誘導体 |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US20070112015A1 (en) * | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
HUE031466T2 (hu) | 2005-11-24 | 2017-07-28 | Dompe Farm Spa | (R)-arilalkilamino származékok és azokat tartalmazó gyógyászati készítmények |
WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
EP2077842A2 (en) | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
AU2008272437A1 (en) | 2007-06-29 | 2009-01-08 | Torrent Pharmaceuticals Ltd. | Novel substituted piperidones as HSP inducers |
WO2010019210A2 (en) | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
EP3101031A1 (en) | 2008-11-10 | 2016-12-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
ES2734746T3 (es) | 2008-12-22 | 2019-12-11 | Chemocentryx Inc | Antagonistas de C5aR |
US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
CA2877526A1 (en) | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
PT3200791T (pt) * | 2014-09-29 | 2020-05-06 | Chemocentryx Inc | Processos e intermediários na preparação de antagonistas c5ar |
CA3010735C (en) | 2016-01-14 | 2023-06-13 | Chemocentryx, Inc. | Use of n-benzoyl-2-phenyl-3-phenylcarbamoyl-piperidin derivative for treating complement 3 glomerulopathy |
-
2011
- 2011-06-24 SI SI201131229T patent/SI2585064T1/sl unknown
- 2011-06-24 CN CN201180039245.XA patent/CN103068385B/zh active Active
- 2011-06-24 JP JP2013516840A patent/JP2013529647A/ja not_active Withdrawn
- 2011-06-24 ES ES11799027.5T patent/ES2632975T3/es active Active
- 2011-06-24 BR BR112012033075-6A patent/BR112012033075B1/pt active IP Right Grant
- 2011-06-24 US US13/806,339 patent/US9126939B2/en active Active
- 2011-06-24 PL PL11799027T patent/PL2585064T3/pl unknown
- 2011-06-24 EP EP11799027.5A patent/EP2585064B1/en active Active
- 2011-06-24 PT PT117990275T patent/PT2585064T/pt unknown
- 2011-06-24 DK DK11799027.5T patent/DK2585064T3/en active
- 2011-06-24 RS RS20170761A patent/RS56332B1/sr unknown
- 2011-06-24 WO PCT/US2011/041910 patent/WO2011163640A1/en active Application Filing
- 2011-06-24 HU HUE11799027A patent/HUE033644T2/en unknown
-
2015
- 2015-09-04 US US14/846,487 patent/US9573897B2/en active Active
-
2016
- 2016-03-17 JP JP2016053725A patent/JP6189989B2/ja active Active
-
2017
- 2017-01-06 US US15/400,820 patent/US20170114017A1/en not_active Abandoned
- 2017-07-31 HR HRP20171176TT patent/HRP20171176T1/hr unknown
- 2017-08-03 JP JP2017150928A patent/JP6438086B2/ja active Active
- 2017-10-02 US US15/722,819 patent/US10035768B2/en active Active
-
2018
- 2018-06-27 US US16/020,139 patent/US20190062275A1/en not_active Abandoned
-
2020
- 2020-10-20 US US17/075,131 patent/US20210269398A1/en not_active Abandoned
-
2022
- 2022-09-26 US US17/935,434 patent/US20230102258A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6438086B2 (ja) | 2018-12-12 |
US20170114017A1 (en) | 2017-04-27 |
EP2585064A4 (en) | 2014-01-15 |
US10035768B2 (en) | 2018-07-31 |
US20210269398A1 (en) | 2021-09-02 |
JP2017193586A (ja) | 2017-10-26 |
EP2585064B1 (en) | 2017-05-03 |
RS56332B1 (sr) | 2017-12-29 |
CN103068385A (zh) | 2013-04-24 |
HUE033644T2 (en) | 2017-12-28 |
WO2011163640A1 (en) | 2011-12-29 |
US20180179160A1 (en) | 2018-06-28 |
US9126939B2 (en) | 2015-09-08 |
BR112012033075B1 (pt) | 2021-06-01 |
US9573897B2 (en) | 2017-02-21 |
ES2632975T3 (es) | 2017-09-18 |
JP2013529647A (ja) | 2013-07-22 |
US20160229802A1 (en) | 2016-08-11 |
CN103068385B (zh) | 2015-04-29 |
HRP20171176T1 (hr) | 2017-10-06 |
US20190062275A1 (en) | 2019-02-28 |
PL2585064T3 (pl) | 2017-09-29 |
EP2585064A1 (en) | 2013-05-01 |
SI2585064T1 (sl) | 2017-08-31 |
PT2585064T (pt) | 2017-08-08 |
JP2016130249A (ja) | 2016-07-21 |
JP6189989B2 (ja) | 2017-08-30 |
BR112012033075A2 (pt) | 2017-01-17 |
US20230102258A1 (en) | 2023-03-30 |
US20130172347A1 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2585064T3 (en) | C5aR antagonists | |
US10660897B2 (en) | C5aR antagonists | |
US20110275639A1 (en) | C5aR ANTAGONISTS |